IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans

被引:588
作者
Albertini, RJ
Anderson, D
Douglas, GR
Hagmar, L
Hemminki, K
Merlo, F
Natarajan, AT
Norppa, H
Shuker, DEG
Tice, R
Waters, MD
Aitio, A [1 ]
机构
[1] Univ Leicester, MRC, Toxicol Unit, Biomonitoring & Mol Interact Sect, Leicester, Leics, England
[2] Univ Vermont, Genet Toxicol Lab, Burlington, VT USA
[3] TNO BIBRA Int Ltd, Surrey, England
[4] Dept Hlth & Welf, Environm Hlth Directorate, Bur Chem Hazards, Ottawa, ON K1A 0L2, Canada
[5] Lund Univ, Dept Environm & Occupat Med, Lund, Sweden
[6] Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden
[7] NCI, Genoa, Italy
[8] Leiden Univ, Dept Radiat Genet & Chem Mutagenesis, Leiden, Netherlands
[9] Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Lab Mol & Cellular Toxicol, Helsinki, Finland
[10] Integrated Lab Syst Inc, Res Triangle Pk, NC USA
[11] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA
[12] WHO, Programme Chem Safety, CH-1211 Geneva, Switzerland
关键词
biomarkers; biomonitoring; genotoxic carcinogens; human populations; guideline; WHO;
D O I
10.1016/S1383-5742(00)00049-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The purpose of these guidelines is to provide concise guidance on the planning, performing and interpretation of studies to monitor groups or individuals exposed to genotoxic agents. Most human carcinogens are genotoxic but not all genotoxic agents have been shown to be carcinogenic in humans. Although the main interest in these studies is due to the association of genotoxicity with carcinogenicity, there is also an inherent interest in monitoring human genotoxicity independently of cancer as an endpoint. The most often studied genotoxicity endpoints have been selected for inclusion in this document and they are structural and numerical chromosomal aberrations assessed using cytogenetic methods (classical chromosomal aberration analysis (CA), fluorescence in situ hybridisation (FISH), micronuclei (MN)); DNA damage (adducts, strand breaks, crosslinking, alkali-labile sites) assessed using bio-chemical/electrophoretic assays or sister chromatid exchanges (SCE); protein adducts; and hypoxanthine-guanine phosphoribosyltransferase (HPRT) mutations. The document does not consider germ cells or gene mutation assays other than HPRT or markers of oxidative stress, which have been applied on a more limited scale. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:111 / 172
页数:62
相关论文
共 242 条
[1]   Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers [J].
Abdel-Rahman, SZ ;
El-Zein, RA ;
Zwischenberger, JB ;
Au, WW .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1998, 398 (1-2) :43-54
[2]   QUANTITATION AND VISUALIZATION OF ALKYL DEOXYNUCLEOSIDES IN THE DNA OF MAMMALIAN-CELLS BY MONOCLONAL-ANTIBODIES [J].
ADAMKIEWICZ, J ;
EBERLE, G ;
HUH, N ;
NEHLS, P ;
RAJEWSKY, MF .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1985, 62 (OCT) :49-55
[3]   INDUCTION OF 6-THIOGUANINE-RESISTANT LYMPHOCYTES IN FISCHER-344 RATS FOLLOWING INVIVO EXPOSURE TO N-ETHYL-N-NITROSOUREA AND CYCLOPHOSPHAMIDE [J].
AIDOO, A ;
LYNCOOK, LE ;
MITTELSTAEDT, RA ;
HEFLICH, RH ;
CASCIANO, DA .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1991, 17 (03) :141-151
[4]  
Albertini R. I., 1981, POPULATION BIOL ASPE, P235
[5]   MUTAGENICITY MONITORING IN HUMANS BY AUTORADIOGRAPHIC ASSAY FOR MUTANT LYMPHOCYTES-T [J].
ALBERTINI, RJ ;
SULLIVAN, LM ;
BERMAN, JK ;
GREENE, CJ ;
STEWART, JA ;
SILVEIRA, JM ;
ONEILL, JP .
MUTATION RESEARCH, 1988, 204 (03) :481-492
[6]  
ALBERTINI RJ, 1981, IARC SCI PUBL, V142, P159
[7]   ELEVATED FREQUENCIES OF 6-THIOGUANINE-RESISTANT LYMPHOCYTES IN MULTIPLE-SCLEROSIS PATIENTS TREATED WITH CYCLOPHOSPHAMIDE - A PROSPECTIVE-STUDY [J].
AMMENHEUSER, MM ;
WARD, JB ;
WHORTON, EB ;
KILLIAN, JM ;
LEGATOR, MS .
MUTATION RESEARCH, 1988, 204 (03) :509-520
[8]  
Ammenheuser MM, 1997, ENVIRON MOL MUTAGEN, V30, P131, DOI 10.1002/(SICI)1098-2280(1997)30:2<131::AID-EM5>3.0.CO
[9]  
2-Q
[10]  
Anderson D, 1997, TERATOGEN CARCIN MUT, V17, P29, DOI 10.1002/(SICI)1520-6866(1997)17:1<29::AID-TCM5>3.0.CO